Brief: TScan Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TSC-100 For The Treatment Of Hematologic Malignancies
24/01/2022 13:00
Jan 24 (Reuters) - TScan Therapeutics Inc TCRX.O :
* TSCAN THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR TSC-100 FOR THE TREATMENT OF
HEMATOLOGIC MALIGNANCIES
* TSCAN THERAPEUTICS INC - PHASE 1 TRIAL OF TSC-100 EXPECTED
TO
INITIATE IN FIRST HALF OF 2022
* TSCAN THERAPEUTICS INC - IND FOR TSC-101 ON HOLD PENDING
ADDITIONAL ASSESSMENT OF RISK OF OFF-TUMOR REACTIVITY
Source text for Eikon: ID:nGNX3bf4pq
Further company coverage: TCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing